Update (July 5, 2026): Ocular FIP and Anterior Uveitis in the GS-441524 Era

Bottom line

• In a 2025 case series of 61 FIP cats, 33% (20/61) had ocular disease, with panuveitis the most common presentation (55% of ocular cases) and bilateral involvement in 70%. [1]
• With injectable remdesivir followed by oral GS-441524, clinical uveitis resolved in ~82% (9/11 with follow-up) at a median of 44 days; overall survival was 80%. [1]
• Secondary glaucoma developed in 20%, and 10% required unilateral enucleation for uncontrolled glaucoma — the eye, not the virus, drove the worst outcomes. [1]
• A 2025 systematic review (11 studies, 650 cats) found ocular-only FIP responded to standard dosing (~90.5% success), reinforcing that antiviral therapy — not the eye's isolation — governs the ocular prognosis. [2]

Clinical facts

• FIP ocular disease is a pyogranulomatous uveitis. Feline coronavirus replicating in macrophages breaks down the blood–ocular barrier, producing anterior-chamber fibrin, keratic precipitates, and aqueous flare anteriorly, plus pyogranulomatous chorioretinitis, retinal vasculitis with perivascular cuffing, and exudative retinal detachment posteriorly. [3]
• Ocular signs are a recognized, not rare, feature. One in three FIP cats in the 2025 series had ocular involvement; panuveitis (55% of ocular cases) outnumbered isolated anterior (20%) or posterior (25%) uveitis, and most were bilateral (70%). [1]
• The eye can be the presenting or isolated organ system. In the 2025 systematic review, ocular-only FIP was a distinct, treatable category with outcomes nearly matching uncomplicated cases. [2]
• Ocular pressure — not viral clearance — is the salvage-threatening complication. Secondary glaucoma affected 20% and drove all enucleations (10%) in the case series. [1]
• FIP historically sits among the leading infectious differentials for feline uveitis alongside FeLV and FIV. [3]

Want to pressure-test a specific case against this evidence? Ask Voyage ForVets about ocular FIP →

What the evidence shows

Anchor — Andrews et al., JVIM 2025 (observational case series). Across 61 cats diagnosed with FIP between October 2021 and December 2022, 20 (33%) presented with ocular disease. Panuveitis was the dominant phenotype (11/20; 55%), followed by posterior uveitis (5/20; 25%) and anterior uveitis (4/20; 20%); involvement was bilateral in 70% (14/20). Antiviral therapy was the backbone: 85% (17/20) received injectable remdesivir first — 71% at high dose (15–20 mg/kg) — transitioning to oral GS-441524 (median 79 days). Among the 11 cats with ophthalmic follow-up, uveitis resolved clinically in 9 (82%) after a median of 44 days. Overall survival was 80% (16/20). The dominant ocular complication was pressure-related: secondary glaucoma in 20% (4/20), with 10% (2/20) undergoing unilateral enucleation for uncontrolled glaucoma. [1]

Supporting — Gokalsing et al., Pathogens 2025 (systematic review, 2018–2024). Pooling 11 studies and 650 GS-441524–treated FIP cats, the combined treatment success rate was 84.6% (550/650 survived in remission), with most protocols treating for at least 12 weeks at 4–10 mg/kg once daily. Critically for the ocular question, ocular-only cases achieved a 90.5% success rate — nearly matching uncomplicated FIP — indicating that standard systemic dosing typically suffices for ocular disease and the eye is not a pharmacologic sanctuary requiring neuro-tier escalation. [2]

Mechanistic context — Colitz, Clin Tech Small Anim Pract 2005. FIP "breaks down the blood-ocular-barrier causing pyogranulomatous uveitis and fibrinous exudation into the anterior chamber," while posterior involvement yields "pyogranulomatous chorioretinitis and retinal vasculitis manifested as perivascular cuffing, exudative retinal detachment, and optic neuritis." This histopathologic picture explains why the presentation is a panuveitis rather than an isolated anterior process, and why FIP belongs on the short list of infectious uveitis differentials in the cat. [3]

How this fits clinical practice

The GS-441524 era has changed the framing of ocular FIP from a near-uniformly fatal sign to a treatable manifestation of a treatable disease. A few practice-relevant implications follow from this evidence summary:

• Treat the systemic disease, and the eye usually follows. Both the case series (82% uveitis resolution) and the systematic review (90.5% success in ocular-only disease) point to antiviral therapy as the determinant of ocular outcome. The blood–ocular barrier that FIP disrupts does not appear to create a sanctuary demanding routine neuro-tier dose escalation for eyes alone. [1][2]
• Watch intraocular pressure, not just inflammation. With secondary glaucoma affecting one in five cats and accounting for every enucleation in the series, IOP monitoring during antiviral therapy is the salvage-relevant surveillance point. Resolution of flare does not guarantee a pressure-safe eye. [1]
• Keep FIP on the infectious-uveitis differential list. A young cat with bilateral panuveitis — fibrin, keratic precipitates, chorioretinitis, or exudative retinal detachment — warrants FIP consideration alongside FeLV, FIV, and toxoplasmosis, with confirmation resting on the full clinical, clinicopathologic, and (where available) effusion/tissue picture. [3]
• Set expectations from data, not anecdote. Median time to uveitis resolution was ~44 days; a bilateral panuveitis is the modal presentation; and median oral GS-441524 duration in the series was well within the ≥12-week standard. These figures let you counsel owners on a realistic timeline. [1][2]

This is an evidence summary, not a treatment protocol; drug selection, dosing, and monitoring must be individualized to the patient and reconciled with current product availability and regulatory status in your jurisdiction.

Have a bilateral-panuveitis cat on your table today? Bring the case to Voyage ForVets →

References

1. Andrews ALMM, et al. Ocular manifestations of feline infectious peritonitis (observational case series). Journal of Veterinary Internal Medicine. 2025;39(6):e70253. https://pmc.ncbi.nlm.nih.gov/articles/PMC12489177/
2. Gokalsing D, Ferrolho J, Gibson W, Vilhena H, Anastácio S. Efficacy of GS-441524 for Feline Infectious Peritonitis: A Systematic Review (2018–2024). Pathogens. 2025;14(7):712. https://pmc.ncbi.nlm.nih.gov/articles/PMC12298711/
3. Colitz CMH. Feline uveitis: diagnosis and treatment. Clinical Techniques in Small Animal Practice. 2005;20(2):117–120. https://pmc.ncbi.nlm.nih.gov/articles/PMC7110830/

Changelog

• 2026-07-05: First published.